EUVIMEDEUVIMED entdecken
Crossref

A Review of Daptomycin vs. Vancomycin for Susceptible Infections: Is One Superior for Outpatient Parenteral Antibiotic Treatment (OPAT)?

Daniel Decker

Infusion Journal · 2023

DOI: 10.70776/kdok3900 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infusion Journal, 2023. Verfasst von Daniel Decker. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Outpatient Parenteral Antibiotic Treatment (OPAT) is becoming a more frequent modality of completing a patient’s antimicrobial treatment to save on hospitalization costs and decrease the risk of nosocomial infections. The use of vancomycin, a widely used medication in OPAT, may mitigate some of those savings due to dosing and lab monitoring challenges, adverse drug reactions (ADRs), clinical failure rate, and rehospitalization risk associated with the drug. The objective of this review is to examine if daptomycin is a safer, more effective, and cost-saving medication to the health care continuum when used in the OPAT setting.

Methods

A literature review was conducted to evaluate the comparative rate of effectiveness, treatment failure due to adverse event (ADE), patient satisfaction, antimicrobial stewardship concerns, and potential cost comparisons of daptomycin and vancomycin.

Results

Daptomycin was shown to have a higher clinical success rate when used in OPAT vs. inpatient (94.6% vs. 86.3%) and a higher success rate vs. standard therapy for S. aureus when used in OPAT (90% vs. 83%). Compared to vancomycin, daptomycin decreased rate of clinical failure (OR 0.58), had a lower rate of discontinuation due to ADE (OR 0.15), less severe ADE, was associated with higher patient satisfaction, and is considered the superior treatment at a willingness to pay threshold above $15,000 for severe infections.

Conclusion

According to the literature review, daptomycin may be superior to vancomycin for severe infections in the OPAT setting. Key Words: daptomycin, vancomycin, OPAT, AKI, WTP

Zitieren

APA

Decker, D. (2023). A Review of Daptomycin vs. Vancomycin for Susceptible Infections: Is One Superior for Outpatient Parenteral Antibiotic Treatment (OPAT)?. Infusion Journal. https://doi.org/10.70776/kdok3900

Vancouver

Decker D. A Review of Daptomycin vs. Vancomycin for Susceptible Infections: Is One Superior for Outpatient Parenteral Antibiotic Treatment (OPAT)?. Infusion Journal. 2023. doi:10.70776/kdok3900

BibTeX
@article{Decker2023,
  author = {Decker, Daniel},
  title = {A Review of Daptomycin vs. Vancomycin for Susceptible Infections: Is One Superior for Outpatient Parenteral Antibiotic Treatment (OPAT)?},
  journal = {Infusion Journal},
  year = {2023},
  doi = {10.70776/kdok3900}
}
Kostenlos starten →